Itepekimab Failure A Setback For Sanofi And Regeneron

I publish my best ideas and top coverage in the Growth Stock Forum . We focus on attractive risk/reward situations and track each of our portfolio stocks, Top Picks and Trading Ideas closely. If you're interested in finding great growth stocks, consider signing up to Growth Stock Forum. Join by June 9, to lock in the current rates before prices increase.Shares of Sanofi (NASDAQ: SNY ) and its partner Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) are down today after the companies announced that itepekimab ...